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Abstract: Tourette syndrome is a common childhood-onset neuropsychiatric disorder 
characterized by chronic tics and frequent comorbid conditions such as attention deficit 
disorder. Most currently used tic-suppressing drugs are frequently associated with serious 
adverse events. Thus, alternative therapeutic agents with more favorable side-effect profiles 
are being evaluated. New hypotheses and recent studies involving GABAergic system in the 
pathophysiology of Tourette syndrome suppose a reason for the evaluation of GABAergic 
drugs. Levetiracetam is a drug with an atypical GABAergic mechanism of action that might be 
expected to improve tics. Although trials performed to evaluate the efficacy of levetiracetam 
in the treatment of Tourette syndrome have provided conflicting results, it may be useful in 
some patients. The established safe profile of levetiracetam makes this drug an alternative for 
treatment if intolerance to currently used drugs appears, but additional evaluation with larger 
and longer duration controlled studies are necessary to assess the real efficacy in patients 
with Tourette syndrome.
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Tourette syndrome: Introduction
Tourette syndrome (TS) is a childhood-onset neuropsychiatric disorder characterized 
by multiple chronic motor and vocal tics with a waxing and waning, fluctuating course. 
TS is a common disorder, with a prevalence of 1%–3% in school-age children and 
0.5% in adolescents.1,2
In the majority of patients with TS, tics are associated with other disturbances 
such as attention deficit hyperactivity disorder (ADHD), obsessive-compulsive disor-
der (OCD), learning difficulties, emotional problems, mood and anxiety symptoms, 
oppositional defiant disorder, and other disruptive behaviors. These comorbidities 
complicate the outcome of the condition, with negative effects on peer acceptance, 
self-esteem and academic performance.3,4
Pathogenesis of Tourette syndrome
The findings from the preceding studies support the notion that TS is a complex genetic 
disorder of synaptic neurotransmission that involves basal ganglia and frontocortical 
circuits. Anatomical and functional neuroimaging studies have shown abnormalities 
in prefrontal cortical, paralimbic and striatal regions of the brain. Abnormal activity in 
the cortico-striato-thalamo-cortical pathways are involved in TS and its accompanying 
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Several neurotransmitters are involved in these pathways, 
although it is widely believed that abnormalities of dopamine 
neurotransmission play a primary role in the physiopathology 
of TS. This hypothesis arises, in part, from evidence from 
pharmacological trials of therapeutic response to blockade of 
dopamine receptors, several functional imaging studies, and 
post-mortem studies.9–11 However, in spite of the evidence 
implicating dopaminergic dysfunction in TS, other neuro-
pathologic and functional imaging studies have demonstrated 
contradictory findings.10
Therefore, the precise neurobiologic abnormality remains 
undefined. Other different neurotransmitters within the 
cortico-striato-thalamo-cortical circuits may also be involved 
in physiopathology of TS.7
Classical treatments in Tourette 
syndrome
Although tics tend to fluctuate within short periods of time, 
and improve or resolve over time, especially after puberty, 
tics can impair the quality of life of children and adolescents 
by interfering with social interactions, school performance, 
and activities of daily living.12,13
For patients with mild symptoms, educational and 
  psychological interventions may be sufficient. Drug therapy 
should be considered for patients whose symptoms interfere 
with their quality of life.
Treatment of tics in TS is symptomatic. The goals of 
  treatment should be to reduce the severity, frequency, and dis-
ruptive impact of symptoms, to manage associated psychiatric 
and learning problems, and to improve social functioning.13
The presence of comorbidities can complicate the treat-
ment of patients with TS. Therapy must be individualized, 
and the most troublesome symptoms should be targeted first. 
Treatment of comorbid behavioral symptoms usually exerts a 
significant beneficial effect on tics. In other patients, a reduc-
tion in tics might improve self-esteem, which in turn results 
in improved behavior and school performance.
There is no ideal anti-tic pharmacotherapy. Drugs have 
highly variable results and, unfortunately, are often associated 
with side-effects.6,13–16 The most widely used treatments have 
consisted of neuroleptics and alpha-2 adrenergic agents.
Dopamine receptor-blocking drugs (neuroleptics) are 
considered the most effective tic-suppresing agents.   Classical 
or typical neuroleptics have shown great efficacy in con-
trolled clinical trials,17,18 but frequent side-effects often limit 
their usefulness.6,19
Alpha-2 adrenergic agents (clonidine and guanfacine) are 
better tolerated but may be not as effective as neuroleptics. 
They are a good alternative for patients with tics and ADHD, 
because both conditions may respond.20,21
The atypical neuroleptics risperidone22–24 and olanza-
pine25,26 showed efficacy in randomized, controlled trials. 
Although associated with fewer side-effects than typical 
neuroleptics, these are still frequent,6,16 and children may 
be more vulnerable than adults.27 Attention must be paid to 
sedation, weight gain, extrapyramidal reactions, electrocar-
diographic alterations, and development of the metabolic 
syndrome (obesity, dyslipidemia, hypertension, and impaired 
glucose metabolism).28,29
Because of frequent side-effects, multiple non-neuroleptic 
alternative medications and non-pharmacological treatments 
have been evaluated for the treatment of tics.6,9,12,30
implication of gamma-aminobutyric acid 
(GABA) in Tourette syndrome
The pathophysiology of TS is not fully understood, but basal 
ganglia dysfunction involving GABAergic neurons is one 
proposed cause of tics.10
Aberrant development of GABAergic circuits has been 
implicated in TS. In one study, marked alteration in the 
distribution of GABAergic neurons was found through 
neuropathological examination of basal ganglia tissue from 
TS patients. A decreased number and density of GABAergic 
interneurons in the striatum and external segment globus pal-
lidus, as well as an increase in the number and proportion of 
GABAergic projection neurons of the internal segment of the 
globus pallidus were found. The authors speculated that these 
alterations would be consistent with a developmental defect 
in tangential migration of some GABAergic neurons.31
Many inhibitory GABAergic interneurons of the cerebral 
cortex migrate tangentially from the same embryogenic 
regions in the ganglionic eminence that also give rise 
to the GABAergic projecting neurons of the striatum.32 
One hypothesis is that an adverse event at a specific devel-
opmental point could impair the appropriate migration and 
maturation of these cells and their assembly into inhibitory 
motor-control circuits.6
It is not completely understood how alterations in 
GABAergic interneurons and globus pallidus projection neu-
rons could lead to a tic disorder. It has been hypothesized that 
in TS, a decrease in striatal GABAergic projections would 
cause insufficient inhibition of excitatory thalamocortical 
neurons, with the ultimate result being increased glutamater-
gic cortical excitation and the appearance of tics.6
Most TS patients over the age of 10 years report 
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and an irresistible urge to perform the tic.33 This probably 
reflects a failure in motor inhibition because of diminished 
ability to appropriately manage sensory inputs.34 Comorbid 
behavioral conditions such as OCD, ADHD, impulse control 
disorder, and intermittent explosive disorder are also related 
to impaired inhibition of inappropriate behaviours. Studies 
with transcranial magnetic stimulation have shown that 
the cortical silent period (period of decreased excitability 
following stimulation) is significantly shortened, and the 
intracortical inhibition is defective in TS patients compared 
to controls.35 This intracortical excitability is also seen fre-
quently in children with ADHD comorbid with a tic disorder. 
Because motor cortex lesions are unlikely in TS patients, 
abnormal intracortical inhibition must be the consequence 
of a dysfunction of the subcortical input.
If these alterations in GABAergic system play a role in 
the pathophysiology of TS, then GABAergic drugs might be 
expected to improve tics. Thus, GABAergic drugs such as 
clonazepam, baclofen, and topiramate have been evaluated 
in treatment of tics, with varying results.
Only a modest tic-suppressing effect has been reported 
with clonazepam in the published case series.14
The GABA-B agonist baclofen has been effective in 
improving tics in one open-label trial, without baseline 
or   follow-up scores.36 In a small, double-blind, placebo-
controlled, crossover study, baclofen had benefit over 
placebo, although the beneficial response was associated 
with improvement in impairment scores rather than with a 
reduction of motor or vocal tics.37
In a randomized, double-blind, placebo-controlled trial, 
topiramate produced a statistically significant improvement 
in TS patients with moderate to severe symptoms.38
Levetiracetam
Levetiracetam (LEV) is a broad-spectrum antiepileptic 
agent that has been used effectively for a variety of seizure 
types in adults and children, and for different psychiatric 
disorders.39,40
LEV does not have a direct effect on GABA receptor-
mediated responses. In vitro findings reveal that LEV behaves 
as a modulator of GABA type A and of the glycine receptors, 
suppressing the inhibitory effect of other negative modulators 
(beta-carbolines and zinc). LEV inhibits the ability of zinc 
and beta-carbolines to interrupt chloride influx, an effect that 
enhances chloride ion influx at the GABA type A receptor 
complex.41,42
A brain-specific binding site for LEV was demonstrated 
for the first time in the brain tissue of rats.43 No specific 
binding was observed in peripheral tissues. More recently, 
this binding site has been identified as the SV2A protein, a 
protein ubiquitously distributed in the central nervous system 
as a component of synaptic vesicles.44 The binding of LEV is 
reversible, saturable, and highly selective to this protein.
SV2A is required for normal neurotransmission. In 
the absence of this protein, action potential-dependent 
  GABAergic neurotransmission is reduced. The exact role 
of the SV2A protein is not fully understood, but it is thought 
to be involved in the regulation of vesicle exocytosis.45
The most frequently reported adverse events with LEV 
include somnolence, irritability, asthenia, headache, dizziness, 
and flu syndrome and are usually mild. In clinical trials, the 
incidence of adverse effects leading to dosage reduction or 
discontinuation was similar to placebo (15% vs 11.6%).39,40 
In a systematic review of adults receiving LEV in long-term 
clinical trials, LEV had a relatively low incidence (13%–16%) 
of adverse psychiatric and behavioral events; apathy, emotional 
lability, agitation, anxiety, depression, anger, hostility, personal-
ity changes, and suicidal ideation are reported events.46 Revers-
ible psychosis associated with LEV therapy was observed in 
children and adolescents.47 These adverse behavioral symptoms 
are more common in patients with epilepsy or a previous history 
of behavioral or psychiatric problems, and can be the primary 
reason for discontinuation of the medication.39,40,47 Adverse 
behavioral events did not appear to be dose-related. Most of 
the behavioral problems associated with LEV therapy resolved 
within days after discontinuation of medication, and were not 
associated with any long-term disability.
The metabolism of levetiracetam is independent of the 
cytochrome P450 system. The absence of hepatic metabolism 
is associated with a very low potential for drug interac-
tions and levetiracetam has no known clinically significant 
interactions.39
Trials with levetiracetam in Tourette 
syndrome
Due to its GABAergic mechanism of action, LEV could 
produce a beneficial effect in patients with TS. Several 
studies, discussed below, were conducted to investigate the 
effectiveness of LEV for the treatment of tics in children and 
adolescents with TS (Table 1).
The most widely-used instruments for measuring tic 
severity in therapeutic trials are the Yale Global Tic Sever-
ity Scale (YGTSS) and Clinical Global Impression (CGI) 
scale.
The YGTSS consists of a rating of severity for motor 
and vocal tics separately, with a scale of 0 to 5 for each tic’s Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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number, frequency, intensity, complexity, and interference 
with daily life. Summation of these scores result in a total tic 
score (TTS). The tic impairment score (TIS) is based on the 
impact of the tic disorder on self-esteem, family life, social 
acceptance, and school performance. TIS is added to TTS 
to obtain the total or global YGTSS score.48
The CGI scale is a seven-point, ordinal scale that uses all 
available information to determine the impact of tics on the 
subject’s quality of life: 1 (healthy), 2 (borderline), 3 (mild), 
4 (moderate), 5 (marked), 6 (severe), and 7 (extreme).
Awaad et al49 suggested in 2005 that levetiracetam may 
be a useful treatment for tics. They conducted a prospective, 
open-label, clinical trial with 60 children and adolescents 
with tics and previously-untreated TS. Patients were treated 
with LEV in doses of 1000–2000 mg/day, and no concomitant 
medications were used. Outcomes were assessed at 1 year 
with the YGTSS and CGI scales and the Revised Conners 
Behavior Scales. The effects on measures of behavior and 
school performance were also assessed. All patients showed 
significant clinical improvements in their vocal and motor 
tics. Also, 43 of the 60 patients showed improvement in their 
behavior and school performance. Three patients discontin-
ued the treatment because of exacerbation of preexisting 
behavioral problems.
In a 4-year follow-up of this prospective, open-label 
study, data were included from 10 additional patients. LEV 
remained 100% effective for tic suppression. Improvements 
were observed within the first 6 weeks of treatment, and 
persisted over time. Also, 70% of patients showed improve-
ment in behavior and school performance.50
A randomized, placebo-controlled, double-blind, cross-
over trial51 was performed to determine whether LEV could 
significantly reduce tics in children and adolescents with TS. 
This study enrolled 22 children aged 8–16 years old with TS, 
Table 1 Studies with Levetiracetam in Tourette syndrome patients
Ref Study type Subjects Intervention Outcomes Remarks and limitations
49 Prospective,  
opel-label
60 patients  
(,18 yrs)
LeV 1–2 g/day 100% improvement of tics  
43/60 improved in behavior and  
school performance
Open-label design
Discontinuation in 3 patients 
because exacerbation of previous 
behavioral or ADHD symptoms.
49 
50
Prospective, open- 
label, 4-years  
follow-up
60 patients + 10  
additional patients  
(6–18 yrs)
LeV 1–2 g/day 100% improvement of tics  
70% improvement in behavior and 
school performance
Open-label study design  
Long follow-up
51 randomized,  
placebo- 
controlled,  
double-blind,  
crossover study
22 patients  
(8–16 yrs)
LeV (750–3000  
mg/day or 30  
mg/kg/day max)  
or placebo in  
randomized  
sequence 4 weeks  
each
Slight reduction in tics with no  
significant differences between  
groups
No improvement in ADHD  
or obsessive-compulsive behaviors
Short duration of treatment phase  
(4 weeks)
52 randomized,  
double-blind,  
crossover study
12 patients  
(8–27 yrs)
LeV (250–1750  
mg/day or max 50  
mg/kg/day) or clonidine  
(0.15–0.3 mg/day)  
in randomized  
sequence 6 weeks  
each
Slight reduction in tics with  
clonidine. No improvement with  
LeV in tics, ADHD or OCD
reduced number of patients  
Under-representation of patients 
with comorbidities
53 Prospective,  
opel-label
29 patients  
(6–17 yrs)
LeV (30–40  
mg/kg/day or 
max 2 g/day),  
12 weeks  
treatment
59% improvement in tics. 26% no  
changes. 15% worsened
Significant improvement in tics in 
ADHD-associated subgroup
Simultaneous treatment with  
methylphenidate
Discontinuation in 11%  
because of adverse effects
54 randomized,  
placebo- 
controlled,  
double-blind
24 patients  
(6–18 yrs) with  
associated epilepsy  
or headache
LeV (500–1250  
mg/day) and  
placebo in  
randomized  
sequence, 
8 weeks  
treatment
9/12 improved in treatment group  
and 1/12 in placebo group.  
Significant improvement in tics with  
LeV
Discontinuation in 1 patient 
because  
of adverse effects 
Abbreviations: Ref, reference list item number; LEV, levetiracetam; ADHD, attention deficit hyperactivity disorder; OCD, obsessive-compulsive disorder.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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with moderate to moderately severe tics. In a randomized 
drug sequence, patients received 4 weeks of LEV with a 
maximum dosage of 30 mg/kg/day, or placebo, with a 2-week 
intervening wash-out period between cycles. The primary 
outcome measures included the total score from the YGTSS 
and the TTS from the subscale. Measurements were taken at 
the baseline (before randomization), on day 28 (end of phase 
I), on day 42 (end of wash-out period and baseline for phase 
II), and on day 70 (end of phase II). In both placebo and treat-
ment groups, there was a slight reduction in tics compared 
with baseline measures, but no significant difference was 
found between groups. The results were not affected by the 
sequence of treatment. Neither was any difference found in 
secondary outcome measures for tics (tic impairment score 
from subscale of YGTSS and CGI scale) nor any effect on 
attentional symptoms or obsessive-compulsive behaviors.
A randomized, double-blind, flexible-dose, crossover 
study52 compared LEV and clonidine for the treatment of 
tics in TS patients: 12 subjects with moderate to moderately 
severe tics were enrolled. Patients received placebo during 1 
week to screen for high placebo responders. Subsequently, in a 
randomized drug sequence, patients received 6 weeks of LEV 
with a maximum dosage of 50 mg/kg/day or 2500 mg/day, 
or clonidine with a 2-week wash-out period between both 
cycles. Ten patients aged 8–27 years completed the study. Two 
were withdrawn before the medication phase (one because 
of important improvement during the placebo run-in phase, 
and the other as a parental decision). The primary outcome 
measure was the TTS component of the YGTSS. Secondary 
outcome measures included the global score of the YGTSS, 
the CGI scale, and other scales for obsessive-compulsive, 
attention deficit hyperactivity, depression, and anxiety 
symptoms. In this study, a small but statistically significant 
improvement in TTS was fround with clonidine (13% from 
baseline). There was no improvement in any tic scores with 
LEV . Evaluating comorbidities, no significant change in sec-
ondary behavioral measures was demonstrated with clonidine 
or LEV . The most commonly reported side-effect with LEV 
was irritability, in four patients.
A prospective, open-label study53 included 29 patients 
with TS aged 6–17 years. Patients received LEV with a 
dosage of approximately 30–40 mg/kg/day (maximum 
2000 mg/day). Concomitant treatment with neuroleptics, 
clonidine, or methylphenidate was present in more than 
half of the cases. The authors evaluated the scores from the 
YGTSS and modified CGI scale at the beginning of the study 
and at 12 weeks. Twenty-seven patients completed the study. 
Tics improved in 59% patients (markedly, in half of them), 
26% did not reveal significant changes, and tics worsened 
in 15% of cases. In the statistical analysis, a significant 
improvement was observed in TTS and the global score from 
YGTSS and the CGI scale. When the results of two separate 
groups (patients with and without associated ADHD) were 
analyzed, only patients with ADHD-associated diagnosis 
revealed a significant improvement in TTS and CGI. Most 
of these patients (63%) were treated simultaneously with 
methylphenidate. Ten cases (37%) presented adverse effects 
(most frequently, irritability and drowsiness), which caused 
discontinuation of treatment in 3 patients (11%).
A recent prospective, double-blinded, randomized, pla-
cebo controlled study54 included 24 children aged 6–18 years 
old with TS and associated diagnoses of epilepsy (14 patients) 
or headache (10 patients). Children were given LEV (500 to 
1250 mg/day) or placebo in a randomized sequence. Twelve 
patients received LEV: 9 of them showed improvement in tics, 
2 were lost to follow-up, and 1 patient with comorbid ADHD 
and OCD discontinued LEV because of aggressiveness. One 
patient in the placebo group showed a great placebo effect 
with improvement in tics, 2 were lost to follow-up, and the 
remaining nine showed no improvement. Patients receiving 
LEV showed a significant decrease in frequency, interfer-
ence, and impairment of motor and vocal tics in YGTSS. 
Seven patients filled the Conners Parent Rating scale before 
and after treatment. The 4 patients who improved were in 
the LEV group.
Other publications are limited to isolated case reports:
•	 A 23-year-old female with refractory TS whose symp-
toms improved significantly, when treated with LEV , and 
persisted at 4-month follow-up.55
•	 A 25-year-old male with severe and refractory TS, who 
presented an ischemic stroke in association with antiphos-
pholipid syndrome and secondarily epilepsy, was treated 
with LEV, with improvement in both tic disorder and 
epileptic syndrome.56
Discussion
New hypotheses and recent studies involving GABAergic sys-
tem in the pathophysiology of Tourette syndrome propose the 
starting point for therapeutical trials with GABAergic drugs.
First, trials with the GABAergic drug clonazepam 
show only a modest effect. Baclofen did not prove to have 
a clear benefit in suppressing tics in a randomized trial. 
More recently, topiramate showed a beneficial effect in a 
  randomized trial.
LEV, with an atypical enhancing activity at GABA-A 
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promising results were found in open-label studies,49,50,53 and 
in one randomized study54, other controlled trials could not 
demonstrate a benefit.51,52
Several important factors must be taken into account 
when interpreting the results of therapeutic trials in TS 
patients, which may explain the contradictory results 
with LEV .
First, tics have a natural waxing and waning pattern, with 
marked fluctuations in severity and frequency, and usually 
improve over time. Even without intervention, a period of 
severe tics will be followed by one of spontaneous waning. 
This fluctuating course and variability of symptoms in TS 
must be considered when interpreting results of clinical 
studies in these patients.
On the other hand, there is evidence that GABA plays a 
key role in the pathophysiology of anxiety and stress disor-
ders, and for that reason, LEV has a potential efficacy for 
the treatment of anxiety.57,58 Other studies have suggested a 
positive effect of LEV on cognitive functioning. In a study 
with adult patients with partial epilepsy, patients receiv-
ing LEV as an add-on therapy had a significant cognitive 
improvement in attention and oral fluency not related to the 
seizure frequency, probably due to the effects of LEV itself.59 
As tics can be exacerbated by factors such as stress, anxiety, 
and learning difficulties, LEV may indirectly improve tics 
due to an anxiolytic or cognitive effect.
Also, treatment of comorbidities such as ADHD fre-
quently improve tics in TS patients.16,21 In some revised stud-
ies, LEV appears to be effective in patients with comorbid 
ADHD, with improvement in Conners Scale ratings, behavior, 
and school performance, without concomitant treatments.50,54 
In another study, LEV significantly reduced tic scores in TS 
patients with ADHD-associated comorbidity compared to 
patients without ADHD, most of them treated simultaneously 
with methylphenidate.53 Other studies did not demonstrate an 
improvement in ADHD or obsessive-compulsive behaviors 
with LEV .51,52
In addition, tics are characterized by suggestibility, and a 
substantial placebo response has been documented in clinical 
trials for TS, with large fluctuations in severity scores while 
receiving placebo.60,61
LEV is considered a safe drug with infrequent side-
effects, which include behavioral disorders in children. 
Although most TS patients treated with LEV had comorbid 
behavioral problems, this drug was usually well tolerated. 
The most frequently reported adverse events were head-
ache, somnolence, irritability, and asthenia, while more 
serious events requiring withdrawal of treatment were 
unusual   (generally exacerbation of previous behavioral 
disorders such as aggressiveness or impulse behavior 
disorder).
Conclusions
LEV is a drug with potential benefits in alleviating tics 
and neuropsychiatric disorders. Although, at this moment, 
trials performed to evaluate the efficacy of LEV in the treat-
ment of TS have provided conflicting results, it seems to 
be useful in some patients. Children and adolescents with 
associated ADHD may be better candidates for treatment 
with LEV .
The established safety profile of LEV makes this drug 
a better-tolerated alternative for treatment if intolerance to 
currently-used drugs appears. The low risk of drug interac-
tions with LEV might be another consideration for patients 
who require the concurrent use of other medications for 
treating comorbid conditions.
The results of some studies, and its safety profile, make 
LEV an alternative candidate for the treatment of TS. 
  However, additional evaluation with larger, and longer-
duration, controlled studies are necessary to assess the real 
efficacy of LEV in TS.
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